Alexion Pharmaceuticals Inc (NASDAQ:ALXN)
| 102.90 Data as of May 17 |  +1.08 / +1.06%Today’s Change | 81.82 Today|||52-Week Range 119.54 | +9.77% Year-to-Date |
Latest ALXN News | Press Releases
| Bayer's Xofigo Cleared in the US - Analyst Blog May 16 / Zacks.com | Off the Charts May 13 / TheStreet.com |
| Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard May 16 / TheStreet.com | Shire - rarity value May 03 / FT.com |
| 3 Stocks Underperforming Today In The Drugs Industry May 15 / TheStreet.com |
Today’s Trading
| Previous close | 101.82 |
| Today’s open | 102.57 |
| Day’s range | 101.77 - 104.29 |
| Volume | 977,654 |
| Average volume (3 months) | 1,766,452 |
| Market cap | $20.1B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | +40.66% |
| Earnings growth (this year) | +38.62% |
| Earnings growth (next 5 years) | +23.60% |
| Revenue growth (last year) | +41.93% |
| P/E ratio | 71.0 |
| Price/Sales | 15.92 |
| Price/Book | 10.17 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | +1.60 | +2.05% |
| SHPGShire PLC | -0.13 | -0.14% |
| ZTSZoetis Inc | +0.51 | +1.53% |
| VRXValeant Pharmaceutic... | +2.42 | +3.19% |
Data as of 4:05pm ET, 05/17/2013
Financials
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | $0.68 |
| Annual revenue (last year) | $1.1B |
| Annual profit (last year) | $254.8M |
| Net profit margin | 22.73% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer, Treasurer & Director Leonard Bell, MD |
Chief Financial Officer & Executive Vice President Vikas Sinha, MBA, CPA |
Corporate headquarters Cheshire, Connecticut |
Forecasts
